
-
MannKind Corporation NasdaqGM:MNKD MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension. The company's product pipeline includes MNKD-101, a nebulized formulation of clofazimine, which is in Phase 3 study, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, which is in phase 1 clinical study, for the treatment of idiopathic pulmonary fibrosis (IPF); MNKD-301, which is in preclinical stage, for cystic fibrosis; and Pediatric Afrezza, which is in phase 3 clinical trial for the treatment of diabetes mellitus. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India; and co-promotion agreement with Amphastar for marketing of Baqsimi (glucagon) nasal powder. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
Location: 1 Casper Street, Danbury, CT, 06810, United States | Website: https://www.mannkindcorp.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
1.218B
Cash
188M
Avg Qtr Burn
N/A
Short % of Float
8.67%
Insider Ownership
1.86%
Institutional Own.
58.65%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Afrezza® (insulin human) Inhalation Powder Details Diabetes, Type 1 diabetes, Type 2 diabetes | Approved Quarterly sales | |
Tyvaso DPI (Treprostinil Technosphere®) (inhaled treprostinil) Details Pulmonary arterial hypertension, Heart disease | Approved Quarterly sales | |
Afrezza® (insulin human) Inhalation Powder Details Type 1 diabetes, Diabetes, Type 2 diabetes | sNDA Submission | |
Clofazimine inhalation suspension (MNKD 101) Details Nontuberculous mycobacterial lung disease, Lung disease | Phase 3 Update | |
MNKD 201 (nintedanib DPI) Details Lung disease, Idiopathic pulmonary fibrosis | Phase 1 Update |